Related Experiment Videos

Elevated serum Lp(a) concentration and the rare apo(a) phenotype in a patient with myocardial infarction

T Hibino1, N Sakuma, T Hashimoto

  • 1Third Department of Internal Medicine, Nagoya City University Medical School, Japan.

Clinical Cardiology
|September 1, 1996
PubMed

Insights

Elevated lipoprotein(a) [Lp(a)] is a cardiovascular disease risk. This case report details successful treatment of myocardial infarction in a patient with high Lp(a) and a rare apo(a) phenotype.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Genetics

Background:

  • Lipoprotein(a) [Lp(a)] is an established independent risk factor for atherosclerotic cardiovascular disease.
  • Elevated Lp(a) levels contribute significantly to atherogenesis and thrombotic events.
  • Understanding Lp(a) phenotypes is crucial for risk stratification and treatment strategies.

Observation:

  • A patient presented with myocardial infarction.
  • The patient exhibited elevated serum Lp(a) concentration.
  • The patient possessed a rare apolipoprotein(a) [apo(a)] phenotype.

Findings:

  • Successful recanalization of the occluded artery was achieved using tissue plasminogen activator (tPA).
  • This case highlights the potential for thrombolytic therapy in acute cardiovascular events associated with high Lp(a) and rare apo(a) phenotypes.
  • The successful outcome suggests that standard acute treatment protocols may be effective despite unusual Lp(a) profiles.

Implications:

  • This case provides valuable clinical insight into managing acute myocardial infarction in patients with specific Lp(a) risk profiles.
  • It underscores the importance of considering Lp(a) levels and apo(a) phenotypes in cardiovascular risk assessment.
  • Further research into the interaction between Lp(a) phenotypes and thrombolytic efficacy is warranted.

Related Concept Videos